MOTS-c
An exercise mimetic peptide derived from mitochondrial DNA that activates AMPK to restore insulin sensitivity and boost metabolic rate.
Also known as: Mitochondrial-Derived Peptide, Exercise Mimetic
Available on Forge Amino
MOTS-C 10MG — independently lab tested, 99%+ purity, QR-linked COA.
Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.
How It Works
Upregulated during exercise; activates AMPK-FOXA2 pathway to restore insulin sensitivity independent of weight loss. Increases mitochondrial biogenesis, fatty acid oxidation, and oxidative capacity.
Key Benefits
- ✓Restores insulin sensitivity to young-animal levels
- ✓Increased mitochondrial biogenesis
- ✓Enhanced exercise capacity
- ✓Improved glucose tolerance
- ✓Preserved muscle mass
Dosing Protocols
Beginner / Intermediate
Dose
1 mg
Frequency
Once daily subcutaneous (AM)
Cycle Length
Up to 60 days
Notes
Start at 1 mg; reconstitute with greater BAC volume if injection-site reactions occur
Advanced
Dose
5 mg twice weekly, or 10 mg once weekly
Frequency
Subcutaneous
Cycle Length
8-12 weeks
Notes
Lower-frequency maintenance dosing as an alternative to daily
Side Effects & Safety
Common Side Effects
- Injection site reactions (>10% incidence)
- Mild headache
- Transient fatigue
- Flushing or temporary energy fluctuation
Contraindications
- Active cancer
- Concurrent metformin or thiazolidinediones
- Type 1 diabetes (hypoglycemia risk)
- Pregnancy and breastfeeding
Stacking & Synergies
These compounds have complementary mechanisms and may enhance results when used together.
Key Takeaway
Get exercise benefits without the gym: MOTS-c mimics endurance training to restore insulin sensitivity.
Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.